KU-19-19

KU-19-19

Cat.No.: CSC-C0442

Species: Homo sapiens (Human)

Source: Bladder

Morphology: epithelial-like cells growing adherently in monolayers

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0442
Description
Established from the invasive transitional cell carcinoma of the bladder (grade 3, pT3b) of a 76-year-old man in 1993; described as secreting several hematopoietic cytokines and chorionic gonadotropin
Species
Homo sapiens (Human)
Source
Bladder
Recommended Medium
Culture Properties
monolayer
Morphology
epithelial-like cells growing adherently in monolayers
Karyotype
Human hypertriploid karyotype - 74(70-75)<3n>XXX, +1, +5, +6, -7, +9, -11, +12, +15, +16, -17, -18, +19, +21, -22, +2mar - add(1)(p32-34)/del(1)(p34), add(4)(q35)x1-2, del(5)(q14.2), add(6)(q11), del(11)(p14), add(12)(q24)/der(12)t(12;17)(q24;q12-22), add
Reference
Disease
Bladder Carcinoma
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization assays
Immunology: cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17 +, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM -, GFAP -, neurofilament -, vim
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 1-2 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
KU 19-19; KU19-19; KU1919; Keio University-19-19
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KU-19-19 is a human bladder carcinoma cell line with distinct advantages for studying transitional cell carcinoma biology, tumor microenvironment interactions, and cytokine-mediated signaling. This epithelial cell line was established in 1993 by a Japanese research team from an invasive transitional cell carcinoma of the bladder (grade 3, pT3b) obtained from a 76-year-old male patient who exhibited marked leukocytosis. The cell line grows adherently as epithelial-like cells in monolayers under standard culture conditions, with a doubling time of approximately 48 hours.

A defining feature of KU-19-19 cells is their ability to constitutively produce and secrete multiple hematopoietic growth factors. Conditioned medium from KU-19-19 cultures contains high levels of granulocyte colony-stimulating factor (G-CSF, exceeding 5 ng/mL), as well as GM-CSF, M-CSF, stem cell factor (SCF), interleukin-6 (IL-6), and interleukin-8 (IL-8). These secreted factors vigorously stimulate proliferation of growth factor-dependent hematopoietic cell lines in a dose-dependent manner, confirming their functional biological activity. This robust secretory profile makes KU-19-19 a practical source for G-CSF purification and a versatile platform for tumor-hematopoietic cell interaction studies.

KU-19-19 cells exhibit constitutive activation of NF-κB, a transcription factor frequently dysregulated in advanced malignancies. When implanted, these cells form tumors in nude mice, associated with severe neutrophilia in peripheral blood, recapitulating the paraneoplastic leukocytosis observed in the original patient. Numerous studies have leveraged KU-19-19 cells to evaluate drug candidates such as the NF-κB inhibitor DHMEQ and natural compounds active against bladder cancer progression, demonstrating their broad utility in anticancer research.

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

PLOS ONE | DOI | Paper |

Background

ARQ 092 and ARQ 751 are selective allosteric pan-AKT inhibitors that bind inactive AKT1-WT and AKT1-E17K, blocking phosphorylation and plasma membrane translocation. In endometrial PDX and other xenograft models, both compounds show strong antitumor activity; ARQ 092 enhances paclitaxel or trastuzumab effects. Across 240 cancer cell lines, sensitivity is enriched in leukemia, breast, endometrial and colorectal cancers, and PIK3CA/PIK3R1 mutations predict response better than PTEN loss. These findings support AKT1-E17K and PIK3CA/PIK3R1 as biomarkers and clinical development of ARQ 092/ARQ 751.

Key Findings

Biochemical and cellular assays show ARQ 092 and ARQ 751 bind unphosphorylated full-length AKT1-WT and AKT1-E17K with nanomolar affinity and inhibit AKT phosphorylation. They prevent both growth-factor-induced and constitutive AKT1-E17K plasma membrane translocation, unlike MK-2206 and GDC-0068. In AN3CA, MDA-MB-453, NCI-H1650 and KU-19-19 cells, both compounds suppress AKT substrates and mTORC1 readouts; ARQ 751 is more potent. In an AKT1-E17K endometrial PDX model, ARQ 092 and ARQ 751 produce dose-dependent tumor growth inhibition and delay regrowth. ARQ 092 also shows antitumor activity in AN3CA, KPL-4 and ZR-75-1 xenografts, and combines with paclitaxel/trastuzumab. OncoPanel 240 analysis shows PIK3CA/PIK3R1 mutant cell lines are more sensitive to ARQ 092/ARQ 751 than wild-type or PTEN-mutant lines, suggesting PIK3CA/PIK3R1 and AKT1-E17K as predictive biomarkers.

Contribution

Creative Bioarray provided the KU-19-19 bladder cancer cell line, which harbors AKT1-E17K/E49K and NRAS Q61R mutations. This cell line was used to evaluate AKT pathway inhibition and antiproliferative sensitivity of ARQ 092, ARQ 751, MK-2206 and GDC-0068, supporting the study’s mutant-AKT and pathway-dependency analyses.

Comparison of AKT pathway inhibition by ARQ 092, ARQ 751, MK-2206, and GDC-0068 in MDA-MB-453, NCI-H1650, and KU-19-19 cells.
Fig. 1. Comparison of AKT pathway inhibition by ARQ 092, ARQ 751, MK-2206, and GDC-0068 in MDA-MB-453, NCI-H1650, and KU-19-19 cells.

Cytotoxicity of 212Pb-Labeled Anti-PTK7 Antibody in 2D Adherent and 3D Multicellular Bladder Cancer Models

This study evaluated the preclinical efficacy of [212Pb]Pb-TCMC-chOI-1, a 212Pb-labeled antibody targeting PTK7, for targeted alpha-emitting radionuclide therapy in bladder cancer using 2D adherent cultures (clonogenic assay) and 3D multicellular spheroid models (spheroid growth inhibition).

[212Pb]Pb-TCMC-chOI-1 treatment resulted in activity- and time-dependent cytotoxicity, with enhanced sensitivity observed in cell lines with higher PTK7 levels. In clonogenic assays, the activity concentration required for 50% growth reduction was 48-74 kBq/mL, corresponding to 22-51 bound and 9-16 internalized 212Pb atoms per cell. In 3D models, similar therapeutic effects were observed despite significantly lower activities (values of approximately 1 and 30 kBq/mL for KU-19-19 and 647-V cells, respectively), suggesting a more pronounced cross-fire effect. Flow cytometry demonstrated treatment-induced DNA damage, cell cycle perturbations and cell death, with response patterns correlating with overall treatment sensitivity. RT-112 and KU-19-19 cells showed superior responses compared to 647-V and T-24 cells, consistent with their higher PTK7 expression.

These findings support PTK7 as a therapeutic target for bladder cancer and demonstrate the potential of [212Pb]Pb-TCMC-chOI-1 for targeted alpha-emitting radionuclide therapy.

Cytotoxicity of [212Pb]Pb-TCMC-chOI-1 in 3D multicellular models.

Fig. 2. Growth inhibition of bladder cancer spheroids treated with [212Pb]Pb-TCMC-mAbs (Lindland, Kim, and Asta Juzeniene. 2025).

Assessment of cell viability, cell cycle progression, and DNA damage.

Fig. 3. Cell viability, apoptosis, DNA damage, and mitotic analysis in KU-19-19 and 647-V cells following [212Pb]Pb-TCMC-chOI-1 treatment (Lindland, Kim, and Asta Juzeniene. 2025).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products